LncRNA MALAT1 as a potential diagnostic and therapeutic target in kidney diseases

Bhupendra Puri; Syamantak Majumder; Anil Bhanudas Gaikwad

doi:10.1016/j.prp.2024.155783

journal article Feb 01, 2025

LncRNA MALAT1 as a potential diagnostic and therapeutic target in kidney diseases

Bhupendra Puri Syamantak Majumder Anil Bhanudas Gaikwad

Pathology - Research and Practice Vol. 266 pp. 155783 · Elsevier BV

View at Publisher Save 10.1016/j.prp.2024.155783

Topics

No keywords indexed for this article. Browse by subject →

References

54

[1]

Luyckx "Sustainable development goals relevant to kidney health: an update on progress" Nat. Rev. Nephrol. (2021) 10.1038/s41581-020-00363-6

[2]

Kellum Acute kidney injury, Nat. Rev. Dis. Prim. (2021) 10.1038/s41572-020-00234-1

[3]

Eckardt "Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference" Kidney Int (2023) 10.1016/j.kint.2023.05.013

[4]

Tuttle "Molecular mechanisms and therapeutic targets for diabetic kidney disease" Kidney Int (2022) 10.1016/j.kint.2022.05.012

[5]

Yoo "Macrophage transcription factor TonEBP promotes systemic lupus erythematosus and kidney injury via damage-induced signaling pathways" Kidney Int (2023) 10.1016/j.kint.2023.03.030

[6]

Alhammadi "The role of RNA-modifying proteins in renal cell carcinoma" Cell Death Dis (2024) 10.1038/s41419-024-06479-y

[7]

K.J. Jager, et al., sA single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases, Kidney Int, Oxford University Press,96 (5), pp. 1803–1805. http://doi.org/10.1038/s41419-024-06479-y. 10.1093/ndt/gfz174

[8]

Mattick "Long non-coding RNAs: definitions, functions, challenges and recommendations" Nat. Rev. Mol. Cell Biol. (2023) 10.1038/s41580-022-00566-8

[9]

Statello "Gene regulation by long non-coding RNAs and its biological functions" Nat. Rev. Mol. Cell Biol. (2021) 10.1038/s41580-020-00315-9

[10]

Puri "Significance of LncRNAs in AKI-to-CKD transition: a therapeutic and diagnostic viewpoint" Life Sci (2024) 10.1016/j.lfs.2024.122509

[11]

B. Puri, S. Majumder, A.B. Gaikwad, Novel dysregulated long non-coding RNAs in the acute kidney injury-to-chronic kidney diseases transition unraveled by transcriptomic analysis, Pharmacol. Res. Perspect. 12 (6) (2024) e70036, http://doi.org/10.1002/prp2.70036. 10.1002/prp2.70036

[12]

Zhou "Long non-coding RNAs as novel diagnostic and therapeutic targets in kidney disease" Chronic Dis. Transl. Med. (2019)

[13]

Hou "Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance" Biomark. Res. (2023) 10.1186/s40364-023-00467-8

[14]

G. Arun, D. Aggarwal, D.L. Spector, MALAT1 long non-coding RNA: functional implications, Non-Coding RNA 6 (2) (2020) 22, http://doi.org/10.3390/ncrna6020022. 10.3390/ncrna6020022

[15]

Lu "Knockdown of lncRNA MALAT1 ameliorates acute kidney injury by mediating the miR-204/APOL1 pathway" J. Clin. Lab. Anal. (2021) 10.1002/jcla.23881

[16]

Tian "The long non-coding RNA MALAT1 is increased in renal ischemia-reperfusion injury and inhibits hypoxia-induced inflammation" Ren. Fail. (2018) 10.1080/0886022x.2018.1487863

[17]

Ding "Mechanism of long non-coding RNA MALAT1 in lipopolysaccharide-induced acute kidney injury is mediated by the miR-146a/NF-κB signaling pathway" Int. J. Mol. Med. (2018)

[18]

Kölling "Hypoxia-induced long non-coding RNA MALAT1 is dispensable for renal ischemia/reperfusion-injury" Sci. Rep. (2018) 10.1038/s41598-018-21720-3

[19]

A.S. Reddi, Absolute Nephrology Review, Springer, 2022, pp. 211–270. http://doi.org/10.1007/978-3-319-22948-5. 10.1007/978-3-030-85958-9_4

[20]

Carney "The impact of chronic kidney disease on global health" Nat. Rev. Nephrol. (2020) 10.1038/s41581-020-0268-7

[21]

Liu "m6A-induced lncRNA MALAT1 aggravates renal fibrogenesis in obstructive nephropathy through the miR-145/FAK pathway" Aging (2020) 10.18632/aging.102950

[22]

Huang "LncRNA MALAT1-deficiency restrains lipopolysaccharide (LPS)-induced pyroptotic cell death and inflammation in HK-2 cells by releasing microRNA-135b-5p" Ren. Fail. (2021) 10.1080/0886022x.2021.1974037

[23]

Lin "Update of pathophysiology and management of diabetic kidney disease" J. Formos. Med. Assoc. (2018) 10.1016/j.jfma.2018.02.007

[24]

Jiang "Cellular crosstalk of mesangial cells and tubular epithelial cells in diabetic kidney disease" Cell Commun. Signal. (2023) 10.1186/s12964-023-01323-w

[25]

Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications

Vinay Singh Tanwar, Marpadga A. Reddy, Rama Natarajan

Frontiers in Endocrinology 2021 10.3389/fendo.2021.665811

[26]

Yang "lncRNA MALAT1 promotes diabetic nephropathy progression via miR-15b-5p/TLR4 signaling Axis" J. Immunol. Res. (2022)

[27]

Puthanveetil "Long non-coding RNA MALAT 1 regulates hyperglycaemia induced inflammatory process in the endothelial cells" J. Cell. Mol. Med. (2015) 10.1111/jcmm.12576

[28]

LncRNA MALAT1 Aggravates Renal Tubular Injury via Activating LIN28A and the Nox4/AMPK/mTOR Signaling Axis in Diabetic Nephropathy

Panai Song, Yinyin Chen, Zhiwen Liu et al.

Frontiers in Endocrinology 2022 10.3389/fendo.2022.895360

[29]

Liu "LncRNA MALAT1 promoted high glucose-induced pyroptosis of renal tubular epithelial cell by sponging miR-30c targeting for NLRP3" Kaohsiung J. Med. Sci. (2020) 10.1002/kjm2.12226

[30]

lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p/IL6ST Axis

Haozi Huang, Guowei Zhang, Zhenying Ge

Frontiers in Pharmacology 2021 10.3389/fphar.2021.647650

[31]

Zhou "Circulating expression level of LncRNA Malat1 in diabetic kidney disease patients and its clinical significance" J. Diabetes Res. (2020)

[32]

The lncRNA MALAT1 is upregulated in urine of type 1 diabetes mellitus patients with diabetic kidney disease

Cristine Dieter, Natália Emerim Lemos, Eliandra Girardi et al.

Genetics and Molecular Biology 10.1590/1678-4685-gmb-2022-0291

[33]

Aliyi "Treatment outcome and survival status among adult patients treated for lupus nephritis in selected tertiary hospitals of Ethiopia" Sci. Rep. (2024) 10.1038/s41598-024-56317-6

[34]

Yung "Endothelial cell activation and glycocalyx shedding-potential as biomarkers in patients with lupus nephritis" Front. Immunol. (2023) 10.3389/fimmu.2023.1251876

[35]

Yang "Long noncoding RNA MALAT-1 is a novel inflammatory regulator in human systemic lupus erythematosus" Oncotarget (2017) 10.18632/oncotarget.20490

[36]

Szeto "Urinary long non-coding RNA levels as biomarkers of lupus nephritis" Int. J. Mol. Sci. (2023) 10.3390/ijms241411813

[37]

Saleh "Dysregulation of cell-free long non-coding RNAs (NEAT2, CTC-471J1. 2 and lnc-DC) in Egyptian systemic lupus and lupus nephritis patients" Meta Gene (2020) 10.1016/j.mgene.2020.100665

[38]

Hsieh "Renal cell carcinoma" Nat. Rev. Dis. Prim. (2017)

[39]

Z. Zhu, et al., PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives, Mol. Cancer 23 (1) (2024) 146, http://doi.org/10.1186/s12943-024-02059-y. 10.1186/s12943-024-02059-y

[40]

Zhang "Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma" Tumor Biol (2015) 10.1007/s13277-014-2925-6

[41]

Li "Long non‑coding RNA MALAT1 correlates with cell viability and mobility by targeting miR‑22‑3p in renal cell carcinoma via the PI3K/Akt pathway" Oncol. Rep. (2019)

[42]

Wang "Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma" Cell Cycle (2020) 10.1080/15384101.2020.1792667

[43]

Ye "LncRNA MALAT1 modified progression of clear cell kidney carcinoma (KIRC) by regulation of miR-194-5p/ACVR2B signaling" Mol. Carcinog. (2019) 10.1002/mc.22926

[44]

Chen "Biological function and mechanism of MALAT-1 in renal cell carcinoma proliferation and apoptosis: role of the MALAT-1–Livin protein interaction" J. Physiol. Sci. (2017) 10.1007/s12576-016-0486-8

[45]

Hirata "Long noncoding RNA MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and interacts with miR-205" Cancer Res (2015) 10.1158/0008-5472.can-14-2931

[46]

R. Eshraghi, et al., Unveiling the role of long non-coding RNA MALAT1: a comprehensive review on myocardial infarction, Front. Cardiovasc. Med. 11 (2024) 1429858, http://doi.org/10.3389/fcvm.2024.1429858. 10.3389/fcvm.2024.1429858

[47]

Zhang "The long noncoding RNA Malat1: its physiological and pathophysiological functions" RNA Biol (2017) 10.1080/15476286.2017.1358347

[48]

Xia "Knockdown of lncRNA MALAT1 attenuates renal interstitial fibrosis through miR-124-3p/ITGB1 axis" Sci. Rep. (2023) 10.1038/s41598-023-45188-y

[49]

Puri, B., Y.A. Kulkarni, and A.B. Gaikwad, Advances in CRISPR-Cas systems for kidney diseases. 2024 http://doi.org/10.1016/bs.pmbts.2024.07.020. 10.1016/bs.pmbts.2024.07.020

[50]

Xu "Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis" Life Sci (2020) 10.1016/j.lfs.2020.118505

Showing 50 of 54 references

Metrics

9

Citations

54

References

Details

Published: Feb 01, 2025
Vol/Issue: 266
Pages: 155783
License: View

Authors

Anil Bhanudas Gaikwad

Funding

Indian Council of Medical Research Award: 54/14/2022-HUM/BMS

Cite This Article

Bhupendra Puri, Syamantak Majumder, Anil Bhanudas Gaikwad (2025). LncRNA MALAT1 as a potential diagnostic and therapeutic target in kidney diseases. Pathology - Research and Practice, 266, 155783. https://doi.org/10.1016/j.prp.2024.155783

LncRNA MALAT1 as a potential diagnostic and therapeutic target in kidney diseases

You May Also Like